Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vaxcell-Bio Therapeutics Co (323990) Fair Value & Analysis

Healthcare · KR · Market cap 118B KRW

Price4,395 KRW
Fair Value1,046 KRW
Upside-76.2%
Quality95/100
Evidence: Low Range 690.13 KRW – 1,307 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Vaxcell-Bio Therapeutics Co (323990) currently trades at 4,395 KRW, while our model-based Fair Value estimate is 1,046 KRW — implying the stock looks roughly 76.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Vaxcell-Bio Therapeutics Co (323990) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 1,046 KRW versus a price of 4,395 KRW — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 323990?
Our 21-model fair value for Vaxcell-Bio Therapeutics Co is 1,046 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 4,395 KRW.
What is the quality score of 323990?
Vaxcell-Bio Therapeutics Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.